{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-001681","form_type":"8-K","ticker":"XBIO","cik":"0001534525","company_name":"Xenetic Biosciences, Inc.","filed_at":"2023-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.477106+00:00","generated_at":"2026-06-17T18:11:33.987723+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Xenetic Biosciences FY 2022 net loss $6.6M; cash $13.1M; DNase platform advances toward Phase 1","bullets":["Net loss for FY 2022 was approximately $6.6 million; R&D expenses rose 50.8% to $4.8M.","Cash at year-end totaled $13.1 million, expected to fund operations and pipeline development.","Royalty payments from Takeda sublicense were ~$1.7M, up 47.1% YoY.","DNase oncology platform progressing towards first-in-human study combined with checkpoint inhibitors or chemo.","Appointed oncology and NETs experts Allan Tsung, MD and Jonathan Spicer, MD, PhD to Scientific Advisory Board."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-001681","json":"https://secwatch.observer/filing/0001683168-23-001681.json","markdown":"https://secwatch.observer/filing/0001683168-23-001681.md","text":"https://secwatch.observer/filing/0001683168-23-001681.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534525/000168316823001681/0001683168-23-001681-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534525/000168316823001681/xenetic_8k-032323.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T18:11:33.987723+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5228ac1ccdd4e12a432c4abf058d14b641df85da","claim":"Xenetic Biosciences, Inc. reported the full year 2022 results: net income Net loss for the year ended December 31, 2022 was approximately $6.6 million..","evidence_excerpt":"On March 23, 2023, Xenetic Biosciences, Inc. (the “Company”) issued a press release announcing results for the year ended December 31, 2022 and providing a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534525/000168316823001681/0001683168-23-001681-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year 2022"},{"label":"Net income","value":"Net loss for the year ended December 31, 2022 was approximately $6.6 million."},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}